Last reviewed · How we verify
Plegridy (PEGINTERFERON BETA-1A)
Plegridy (generic name: PEGINTERFERON BETA-1A) is a Interferon beta [EPC] Recombinant protein drug developed by Biogen Idec Inc. It is currently FDA-approved (first approved 2014) for Relapsing remitting multiple sclerosis.
Plegridy works by binding to the interferon alpha/beta receptor, which helps to reduce inflammation and slow disease progression in multiple sclerosis.
Plegridy is a protein modality that acts as an agonist to the interferon alpha/beta receptor. It is used to treat Relapsing-Remitting Multiple Sclerosis (RRMS) and is administered via injection.
At a glance
| Generic name | PEGINTERFERON BETA-1A |
|---|---|
| Sponsor | Biogen Idec Inc |
| Drug class | Interferon beta [EPC] |
| Target | Interferon alpha/beta receptor |
| Modality | Recombinant protein |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2014 |
| Annual revenue | 800 |
Mechanism of action
The mechanism by which PLEGRIDY exerts its effects in patients with multiple sclerosis is unknown.
Approved indications
- Relapsing remitting multiple sclerosis
Common side effects
- Injection site erythema
- Influenza-like illness
- Pyrexia
- Headache
- Myalgia
- Arthralgia
- Asthenia
- Injection site pain
- Injection site pruritus
- Chills
- Nausea
- Vomiting
Key clinical trials
- An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
- A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
- Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (NA)
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis (PHASE3)
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (PHASE4)
- Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products (PHASE1)
- Plegridy Satisfaction Study in Participants (PHASE4)
- Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Plegridy CI brief — competitive landscape report
- Plegridy updates RSS · CI watch RSS
- Biogen Idec Inc portfolio CI
Frequently asked questions about Plegridy
What is Plegridy?
How does Plegridy work?
What is Plegridy used for?
Who makes Plegridy?
What is the generic name of Plegridy?
What drug class is Plegridy in?
When was Plegridy approved?
What development phase is Plegridy in?
What are the side effects of Plegridy?
What is Plegridy's annual revenue?
What does Plegridy target?
Related
- Drug class: All Interferon beta [EPC] drugs
- Target: All drugs targeting Interferon alpha/beta receptor
- Manufacturer: Biogen Idec Inc — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Relapsing remitting multiple sclerosis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing